1,786 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Gilbert, P. B., Montefiori, D. C., McDermott, A., Fong, Y., Benkeser, D. C., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O’Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., … Teams, U. S. G. (USG)/CoVPN B. (2021). Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. MedRxiv, 2021.08.09.21261290. https://doi.org/10.1101/2021.08.09.21261290

    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

    1. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., Trotter, A. J., Ashby, D., Barclay, W., Taylor, G., Cooke, G., Ward, H., Darzi, A., … Elliott, P. (2022). SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): A series of cross-sectional random community surveys. The Lancet Respiratory Medicine, 0(0). https://doi.org/10.1016/S2213-2600(21)00542-7

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

    1. Shawna Thomas. (2021, October 13). When asked on @CBSMornings about the company’s vaccine mandate for staff, the CEO of @united airlines also said, “Out of our 67,000 U.S. employees, there are 232 who haven’t been vaccinated. They are going through the termination process.” [Tweet]. @Shawna. https://twitter.com/Shawna/status/1448261664650973186

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

    1. Dowdy, D. (2021, September 21). On the J&J booster news, keep in mind: 1. Median follow-up since 2nd dose was just 36 days, 2. Efficacy vs moderate COVID was 75% globally, and 3. Total number of cases in the US was 15. Please don’t take this to mean that a 2nd dose provides long-term increase in protection. Https://t.co/RnqDNBmwuD [Tweet]. @davidwdowdy. https://twitter.com/davidwdowdy/status/1440323242942554122

    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

    1. Sandra Ciesek. (2021, December 8). Unsere ersten Daten zur Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron https://t.co/w0gHww26sg [Tweet]. @CiesekSandra. https://twitter.com/CiesekSandra/status/1468465347519041539

    1. Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

    1. John Bye [@_johnbye]. (2021, October 6). The new covid sceptic All Party Parliamentary Group on Pandemic Response and Recovery is backed by Gupta and Heneghan’s Collateral Global to the tune of over £30,000. £5,000 in financial benefits plus £25,501—£27,000 benefits in kind (CG is acting as their secretariat). Https://t.co/qll20Sg9aA [Tweet]. Twitter. https://twitter.com/_johnbye/status/1445867760819396608

    1. Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

    1. Dr Dan Goyal. (2022, March 15). What’s been happening This Week in Covid? The schism between reality and policy grew even wider this week... Omicron B.2 sent cases soaring and stock markets sinking! #TheWeekInCovid [Tweet]. @danielgoyal. https://twitter.com/danielgoyal/status/1503699425427968001